Company overview
What Recursion does
Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and development platform it calls the Recursion OS. The company’s approach combines high-throughput automated laboratory experimentation with proprietary multimodal biological and chemical datasets and purpose-built machine learning models, then connects those “dry” and “wet” components in an iterative, lab-in-the-loop cycle intended to accelerate how programs move from target hypotheses through preclinical and clinical execution.